Department of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Department of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Photodiagnosis Photodyn Ther. 2021 Mar;33:102179. doi: 10.1016/j.pdpdt.2021.102179. Epub 2021 Jan 8.
Severe hypotension is a notable adverse event caused by administration of 5-aminolevulinic acid (5-ALA) during photodynamic diagnosis-assisted transurethral resection of bladder tumor (PDD-TURBT). Hypotension can be prolonged following induction of anesthesia and may require continuous administration of a vasopressor. Here, we investigated the risk factors for severe hypotension caused by oral administration of 5-ALA.
A total of 128 patients with bladder tumors who underwent PDD-TURBT using 5-ALA were included in this study. Clinicopathological data were collected retrospectively and the correlations between the incidence of severe hypotension and clinicopathological factors were analyzed.
Severe hypotension developed in 8 cases (6.3 %). Age ≥ 80 years, body mass index (BMI) ≥ 25 (kg/m), and estimated glomerular filtration rate (eGFR) < 45 (mL/min/1.73 m) were significantly correlated with severe hypotension (P = 0.003, 0.017, and 0.027, respectively). Severe hypotension developed in 1 of 89 cases (1.1 %) which have 0 or 1 risk factor, and in 3 of 31 cases (9.7 %) which have 2 risk factors, whereas it developed in 4 of 8 cases (50 %) which have all risk factors. Patients with all risk factors developed severe hypotension significantly more frequently compared with patients with 1 or fewer risk factors (P < 0.001).
Age ≥ 80 years, BMI ≥ 25, and eGFR < 45 are risk factors for severe hypotension in PDD-TURBT using 5-ALA. The risk of developing severe hypotension is extremely high in patients who have all factors. Adjustment of the 5-ALA dose may be desirable in those patients.
在经尿道膀胱肿瘤光动力诊断辅助切除术(PDD-TURBT)中使用 5-氨基酮戊酸(5-ALA)会导致严重低血压,这是一种显著的不良反应。麻醉诱导后低血压可能会持续存在,并可能需要持续给予血管加压药。在此,我们研究了口服 5-ALA 引起严重低血压的危险因素。
共纳入 128 例接受 PDD-TURBT 治疗的膀胱肿瘤患者。回顾性收集临床病理资料,并分析严重低血压发生率与临床病理因素的相关性。
8 例(6.3%)出现严重低血压。年龄≥80 岁、体重指数(BMI)≥25(kg/m)和估算肾小球滤过率(eGFR)<45(mL/min/1.73 m)与严重低血压显著相关(P=0.003、0.017 和 0.027)。0 或 1 个危险因素者中发生严重低血压 1 例(1.1%),2 个危险因素者中发生 3 例(9.7%),而 3 个危险因素者中发生 4 例(50%)。所有危险因素患者发生严重低血压的频率明显高于 1 个危险因素患者(P<0.001)。
年龄≥80 岁、BMI≥25 和 eGFR<45 是 PDD-TURBT 使用 5-ALA 引起严重低血压的危险因素。在所有危险因素患者中,发生严重低血压的风险极高。对于这些患者,可能需要调整 5-ALA 剂量。